Q1 2020 13F Holders as of 3/31/2020
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
19.3M
-
Number of holders
-
248
-
Total 13F shares, excl. options
-
22.8M
-
Shares change
-
+2.5K
-
Total reported value, excl. options
-
$1.66B
-
Value change
-
-$15.1M
-
Put/Call ratio
-
2.04
-
Number of buys
-
105
-
Number of sells
-
-144
-
Price
-
$72.72
Significant Holders of LIGAND PHARMACEUTICALS INC - Common Stock (LGND) as of Q1 2020
310 filings reported holding LGND - LIGAND PHARMACEUTICALS INC - Common Stock as of Q1 2020.
LIGAND PHARMACEUTICALS INC - Common Stock (LGND) has 248 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 22.8M shares
.
Largest 10 shareholders include BlackRock Inc. (2.21M shares), VANGUARD GROUP INC (1.59M shares), JANUS HENDERSON GROUP PLC (1.59M shares), WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC (1.52M shares), STATE STREET CORP (1.25M shares), CARDINAL CAPITAL MANAGEMENT LLC /CT (982K shares), MACQUARIE GROUP LTD (693K shares), WASATCH ADVISORS INC (690K shares), Conestoga Capital Advisors, LLC (649K shares), and VILLERE ST DENIS J & CO LLC (636K shares).
This table shows the top 248 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.